Multiple Sclerosis Market Competitive Landscape Report 2026: Comprehensive Insights on Over 60 Companies and 75 Drugs by Product Type, Development Stage, Administration Route, and Molecule Type
Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Multiple Sclerosis - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering.
The report offers comprehensive insights on over 60 companies and 75 drugs targeting Multiple Sclerosis (MS). It provides a thorough analysis of therapeutics by product type, development stage, administration route, and molecule type, also addressing inactive pipeline products globally.
Multiple Sclerosis is a prevalent neurological disorder among young adults, affecting the axons in the central nervous system. Primarily impacting individuals aged 20-40, it is diagnosed in around 2.5 million people worldwide, with a higher incidence in females. Disease-modifying therapies (DMT) are essential in managing MS, alongside symptomatic relief therapies. Currently, 12 DMTs are FDA-approved, including notable treatments like Tecfidera, Lemtrada, Plegridy, and Copaxone since 2013.
For further insights, the report delivers an in-depth commercial assessment of MS drugs focusing on collaborations, licensing, and acquisitions among key players. Key questions are addressed, including the development status of drugs, collaboration strategies, and trends in MS therapeutics.
Key Players in this landscape include Sanofi, Immunic, Tiziana Life Sciences, Biogen, J-Pharma, and Bristol-Myers Squibb among others. The report also examines emerging products such as SAR 441344, IMU-838, and foralumab.
Report Highlights
Key Company and Product Profiles
Key Topics Covered:
Introduction
Executive Summary
Multiple Sclerosis: Overview
Multiple Sclerosis -Analytical Perspective: In-depth Commercial Assessment
Competitive Landscape
Therapeutic Assessment
Multiple Sclerosis: Company and Product Profiles (Marketed Therapies)
TG Therapeutics
BRIUMVI
Multiple Sclerosis: Company and Product Profiles (Pipeline Therapies)
Late Stage Products (Phase III)
Immunic
IMU-838
Mid Stage Products (Phase II)
Tiziana Life Sciences
Foralumab
Early Stage Products (Phase I)
J-Pharma Co., Ltd.
JPH034
Preclinical and Discovery Stage Products
Polpharma Biologics
PB018
Inactive Products
Multiple Sclerosis- Unmet needs
Multiple Sclerosis - Market drivers and barriers
Companies Featured
For more information about this report visit https://www.researchandmarkets.com/r/x37obh
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.